Altimmune (NASDAQ:ALT) is a clinical‐stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies that harness the power of the immune system. The company’s research focuses on unmet medical needs in the fields of vaccines, liver disease and metabolic disorders. By leveraging its proprietary intranasal vaccine platform, Altimmune aims to deliver next‐generation products that improve efficacy, safety and patient compliance compared with traditional injectable formulations.
Altimmune’s lead vaccine candidate, NasoVAX™, is designed to protect against seasonal influenza by eliciting both systemic and mucosal immune responses following a single intranasal dose. The company is also advancing additional programs that apply its nasal delivery technology to respiratory pathogens, including a COVID‐19 vaccine candidate in early clinical testing. Beyond vaccines, Altimmune is developing immunotherapies for chronic liver conditions such as non‐alcoholic steatohepatitis (NASH) and is evaluating novel peptide‐based drugs aimed at addressing obesity and metabolic syndrome.
Founded in 2016 and headquartered in Gaithersburg, Maryland, Altimmune has built a robust development infrastructure with state‐of‐the‐art laboratories and manufacturing partnerships across North America and Europe. Since completing its initial public offering, the company has established strategic collaborations with academic institutions and biotechnology firms to accelerate preclinical research and streamline regulatory pathways. Altimmune’s multidisciplinary team works closely with global health authorities to design clinical trials that could support future product approvals.
Altimmune is led by a seasoned management team with extensive experience in drug development, regulatory affairs and commercialization. The executive leadership and board of directors bring together former senior executives from leading pharmaceutical companies and research institutions. This collective expertise positions Altimmune to advance its diversified pipeline toward pivotal trials and, ultimately, to bring innovative immune‐based products to patients worldwide.
